Table 1.

Summary of OxCaMS trial registration data

Data category	Information
Registry and ID	ISRCTN33631053
Date of registration	8 June 2018
Secondary identifying numbers	IRAS 213212
Sources of financial or material support	Wellcome Trust, NIHR Oxford Health Biomedical Research Centre, NIHR Oxford cognitive health Clinical Research Facility
Sponsor	University of Oxford
Contact for public queries	PJH (paul.harrison@psych.ox.ac.uk) or KEAS (kate.saunders@psych.ox.ac.uk)
Contact for scientific queries	PJH (paul.harrison@psych.ox.ac.uk) or KEAS (kate.saunders@psych.ox.ac.uk)
Public title	OxCaMS
Scientific title	Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep
Countries of recruitment	UK
Health condition studied	Mood instability
Intervention	Nicardipine sustained release (30 mg bd) or placebo, for 14 days
Key inclusion criteria	Score > 7 on Mood Disorder Questionnaire with evidence of functional impairment. Aged 18–35 years
Key exclusion criteria	Current psychotropic medication. Need for urgent psychiatric treatment. Psychiatric disorder or substance misuse which, in the opinion of the investigator, could compromise safety or data quality
Study type	Primary purpose: experimental medicine, exploratory study Allocation: randomised, double-blind, parallel group. 14 day run-in before allocation
Date of first enrolment	December 2017
Target sample size	40
Recruitment status	Recruiting
Primary outcome	Cognitive variability
Key secondary outcomes	Mood variability, behavioural variability, BOLD and MEG signals at rest and during task performance, sleep parameters, calcium channels in leukocytes